SCHEMBL5532034

SCHEMBL5532034

C#Cc1ccc(NC(=O)c2cc(OC)ccc2N(C=O)c2ccc(C=NN(C)CCCN(C)C)cc2F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.34
HSD17B10 Q99714 3/20 0.34
LMNA P02545 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDR P35968 4/20 0.34
F10 P00742 1/20 0.34
ACHE P22303 2/20 0.33
HPGD P15428 2/20 0.33
MAPT P10636 3/20 0.33
HTT P42858 1/20 0.31
RECQL P46063 1/20 0.31
PLAU P00749 1/20 0.31
LCK P06239 1/20 0.31
TEK Q02763 1/20 0.31
MIF P14174 1/20 0.31
POLB P06746 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MAPK1 P28482 1/20 0.31
SIRT2 Q8IXJ6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535973 0.93 LCK (0.33) KDRF10LCKTEK
SCHEMBL5538435 0.90 F10 (0.40) ALDH1A1KDRF10ACHEMAPT
SCHEMBL5528410 0.89 F10 (0.37) KDM4ELMNAALDH1A1F10HPGD
SCHEMBL5533806 0.88 F10 (0.33) F10
SCHEMBL5535752 0.86 F10 (0.32) F10HTTRECQL
SCHEMBL5532522 0.86 POLB (0.37) KDM4EHSD17B10LMNAALDH1A1KDR
SCHEMBL5530436 0.85 F10 (0.34) KDM4EALDH1A1KDRF10HPGD
SCHEMBL5534065 0.85 F10 (0.41) LMNAALDH1A1F10ACHEMAPT
SCHEMBL5533680 0.82 F10 (0.33) KDM4EF10MAPT
SCHEMBL5529930 0.82 F10 (0.35) F10POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 KDM4E 2053/4885HSD17B10 3577/4885LMNA 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.